GlassScriptPhysician profile
Sunana Sohi
NPI 1740449131
$219,872.19
in general payments reported to CMS, 2019-2025
29 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,588 · 2020: $779 · 2021: $4,007 · 2022: $20K · 2023: $10K · 2024: $128K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $161K · Travel and Lodging: $17K · Food and Beverage: $8,073 · Honoraria: $2,750 · Consulting Fee: $2,168 · Education: $19.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,580.50 |
| Travel and Lodging | $16,762.70 |
| Food and Beverage | $8,073.00 |
| Honoraria | $2,750.00 |
| Consulting Fee | $2,167.50 |
| Education | $19.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $141,771.20 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $32,991.22 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $32,902.88 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $3,206.14 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $2,647.96 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,874.32 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $1,512.61 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $915.82 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $563.67 | 2019-2025 | |
| Genzyme Corporation | $287.20 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $189.65 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $171.96 | 2019-2023 | Linzess |
| Ucb, INC. | $123.01 | 2019 | |
| Evoke Pharma, INC. | $119.23 | 2022 | |
| Ferring Pharmaceuticals INC. | $111.73 | 2019-2023 | Rebyota |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $87.53 | 2022-2024 | Ibsrela |
| Braintree Laboratories, INC. | $61.98 | 2019-2021 | |
| Mauna Kea Technologies, INC. | $52.66 | 2023 | |
| Allergan, INC. | $49.50 | 2019-2020 | |
| Shire North American Group INC | $42.37 | 2019 | |
| Qol Medical, LLC | $35.86 | 2019-2025 | Sucraid |
| Lilly USA, LLC | $33.75 | 2025 | Omvoh |
| Gilead Sciences, INC. | $26.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $19.06 | 2021 | |
| Celltrion USA INC. | $19.05 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $14.72 | 2019 | |
| Csl Behring | $14.38 | 2019 | |
| Shionogi INC | $13.38 | 2019 | |
| Medtronic, INC. | $12.87 | 2023 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunana Sohi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.